BSc (Hons), MSc, PhD, EurChem., CSci., CChem. FRSC, FHEA
Oliver Sutcliffe graduated from the University of Liverpool with a BSc (Hons) in Chemical Sciences (1996) and subsequently obtained a PhD in Synthetic Organic Chemistry working on "New Extended Dipolar Systems" under Drs Richard Storr and Thomas Gilchrist from the same institution. In 1999, he joined Professor Martin Bryce's group at the University of Durham as a Postdoctoral Fellow investigating the application of enantiopure ferrocene ligands in asymmetric synthesis, before moving to industry and working as a Medicinal Chemist on the design, development and optimisation of drug molecules for a broad-range of biological targets, including cancer.
He moved to the University of Strathclyde in 2006, obtained an MSc in Pharmaceutical Analysis and after a period at the European Directorate for the Quality of Medicines and Healthcare (EDQM) in Strasbourg was appointed as a lecturer in the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS). In January 2012, Dr Sutcliffe joined the staff at Manchester Metropolitan University as a Senior Lecturer in Psychopharmaceutical Chemistry; Co-Director of the Manchester Centre for the Study of Legal Highs (MCSLH) and Director of MANDRAKE.
In recognition of his contribution to the field of New Psychoactive Substance (NPS) research, Dr Sutcliffe was appointed a Fellow of the Royal Society of Chemistry (FRSC) in August 2016.